J&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue Market

Kenvue plans to start meeting with prospective investors as early as Monday

The division slated to become Kenvue generated $14.95 billion in global sales last year, about 15.7% of Johnson & Johnson’s total. Photo: BRENDAN MCDERMID/REUTERS

Johnson & Johnson is poised to begin a roadshow to pitch shares of its consumer-healthcare business, the producer of household names such as Tylenol, in a test for an IPO market that has been in the doldrums for the past year.

Kenvue Inc. plans to start meeting with prospective investors as early as Monday, people familiar with the matter said. The goal is to raise $3.5 billion or more in the offering at a valuation close to $40 billion, the people said. IPO roadshows typically last anywhere from a few days to a week ahead of the stock’s trading debut.

What's News

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue reading your article with
a WSJ subscription

Subscribe Now

Already a subscriber? Sign In

Sponsored Offers
  • Walmart:
    20% off your order with Walmart promo code
  • Target:
    Target Promo Code: 20% Off Entire Order
  • Groupon:
    Groupon Promo Code - 30% Off Activities, Dining, More
  • eBay:
    30% off eBay coupon
  • JCPenney:
    Extra 25% Off Power Penney Sale | JCPenney Coupon
  • Best Buy:
    Redeem up to $800 Off iPhone 14 series - Best Buy Coupon